person · Reporting owner
TVM Life Science Ventures VII L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acer Therapeutics Inc.ACER · Entity 108116 | Director · 10% owner | August 01, 2018 | August 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acer Therapeutics Inc.
Report date August 01, 2018 · Filed August 22, 2018
Jointly reported with Birner Hubert, Marengere Luc, Fischer Stefan, SCHUHSLER HELMUT, Beeby Reshentha, Leatt Gary
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,697,709 |
Reported balance
After 2018-08-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-08-01 · Purchase · Acquired 275,000 · Balance 1,697,709 F1: These shares are directly held by TVM Life Science Ventures VII L.P. ("TVM VII LP"). TVM Life Science Ventures VII (GP) Ltd. ("TVM VII GP Ltd") is the general partner of TVM VII LP. Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), Helmut Schuhsler ("Schuhsler"), Luc Marengere ("Marengere"), Reshentha Beeby ("Beeby"), and Gary Leatt ("Leatt") are members of the investment committee of TVM VII GP Ltd, which has voting and investment power with respect to these shares. TVM VII GP Ltd, Birner, Fischer, Schuhsler, Marengere, Beeby and Leatt each disclaim any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein, if any. Marengere is a director of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are directly held by TVM Life Science Ventures VII L.P. ("TVM VII LP"). TVM Life Science Ventures VII (GP) Ltd. ("TVM VII GP Ltd") is the general partner of TVM VII LP. Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), Helmut Schuhsler ("Schuhsler"), Luc Marengere ("Marengere"), Reshentha Beeby ("Beeby"), and Gary Leatt ("Leatt") are members of the investment committee of TVM VII GP Ltd, which has voting and investment power with respect to these shares. TVM VII GP Ltd, Birner, Fischer, Schuhsler, Marengere, Beeby and Leatt each disclaim any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein, if any. Marengere is a director of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Jointly reported with Marengere Luc
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy TVM Life Science Ventures VII L.P. | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-03-01 · Other · Disposed 1,545,386 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. F2: Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 5,954 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Disposition to issuer · Disposed 1,449 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-01 · Disposition to issuer · Disposed 8,897 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-07-01 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-01 · Disposition to issuer · Disposed 2,371 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.20 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-03-01 · Disposition to issuer · Disposed 658 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
F2: Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F4: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2018 Filed Aug 22, 2018 16:22 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 275,000 | $18.00 | $4,950,000.00 |
DisclosureSEC source: 0001012975-18-001040 · edgar.xml · nonDerivative · entry 1 TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · Director · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Beeby Reshentha · CIK 0001750983 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,697,709 F1 · ownership.nature: These shares are directly held by TVM Life Science Ventures VII L.P. ("TVM VII LP"). TVM Life Science Ventures VII (GP) Ltd. ("TVM VII GP Ltd") is the general partner of TVM VII LP. Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), Helmut Schuhsler ("Schuhsler"), Luc Marengere ("Marengere"), Reshentha Beeby ("Beeby"), and Gary Leatt ("Leatt") are members of the investment committee of TVM VII GP Ltd, which has voting and investment power with respect to these shares. TVM VII GP Ltd, Birner, Fischer, Schuhsler, Marengere, Beeby and Leatt each disclaim any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein, if any. Marengere is a director of the Issuer. Read SEC document |
| December 12, 2017 Filed Jan 12, 2018 14:33 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 250,000 | $12.00 | $3,000,000.00 |
DisclosureSEC source: 0001012975-18-000059 · edgar.xml · nonDerivative · entry 3 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · Director · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,422,709 F3 · ownership.nature: These shares are directly held by TVM Life Science Ventures VII L.P. ("TVM VII LP"). TVM Life Science Ventures VII (GP) Ltd. ("TVM VII GP Ltd") is the general partner of TVM VII LP. Luc Marengere ("Marengere"), Mark Wanless ("Wanless"), Gary Leatt ("Leatt"), Birner, Fischer and Schuhsler are members of the investment committee of TVM VII GP Ltd, which has voting and investment power with respect to these shares. TVM VII GP Ltd, Birner, Fischer, Schuhsler, Marengere, Wanless and Leatt each disclaim any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein, if any. Marengere is a director of the Issuer. Read SEC document |
| December 12, 2017 Filed Jan 12, 2018 14:33 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 21,271 | $12.00 | $255,252.00 |
DisclosureSEC source: 0001012975-18-000059 · edgar.xml · nonDerivative · entry 2 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · Director · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 248,756 F2 · ownership.nature: The shares are directly held by TVM Life Science Ventures VI L.P. ("TVM VI LP"). Birner, Schuhsler and Fischer are members of the investment committee of TVM VI Management, a special limited partner of TVM VI LP, with voting and dispositive power over the shares held by TVM VI LP. TVM VI Management, Birner, Schuhsler and Fischer each disclaim beneficial ownership of the shares held by TVM VI LP, except to the extent of any pecuniary interest therein, if any. Read SEC document |
| December 12, 2017 Filed Jan 12, 2018 14:33 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 62,062 | $12.00 | $744,744.00 |
DisclosureSEC source: 0001012975-18-000059 · edgar.xml · nonDerivative · entry 1 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · Director · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 725,844 F1 · ownership.nature: The shares are directly held by TVM Life Science Ventures VI GmbH & Co. KG ("TVM VI"). Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), and Helmut Schuhsler ("Schuhsler") are members of the investment committee of TVM Life Science Ventures Management VI L.P. ("TVM VI Management"), a special limited partner of TVM VI, with voting and dispositive power over the shares held by TVM VI. TVM VI Management, Birner, Schuhsler and Fischer each disclaim beneficial ownership of the shares held by TVM VI, except to the extent of any pecuniary interest therein, if any. Birner is a director of the Issuer. Read SEC document |
| September 19, 2017 Filed Sep 27, 2017 18:34 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | OtherCommon Stock | 1,172,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000726 · edgar.xml · nonDerivative · entry 3 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,172,709 F1 · kind: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F1 · price: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F4 · ownership.nature: These shares are directly held by TVM Life Science Ventures VII L.P. ("TVM VII LP"). TVM Life Science Ventures VII (GP) Ltd. ("TVM VII GP Ltd") is the general partner of TVM VII LP. Luc Marengere ("Marengere"), Mark Wanless ("Wanless"), Gary Leatt ("Leatt"), Birner, Fischer and Schuhsler are members of the investment committee of TVM VII GP Ltd, which has voting and investment power with respect to these shares. TVM VII GP Ltd, Birner, Fischer, Schuhsler, Marengere, Wanless and Leatt each disclaim any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein, if any. Marengere is a director of the Issuer. Read SEC document |
| September 19, 2017 Filed Sep 27, 2017 18:34 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | OtherCommon Stock | 227,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000726 · edgar.xml · nonDerivative · entry 2 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 227,485 F1 · kind: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F1 · price: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F3 · ownership.nature: The shares are directly held by TVM Life Science Ventures VI L.P. ("TVM VI LP"). Birner, Schuhsler and Fischer are members of the investment committee of TVM VI Management, a special limited partner of TVM VI LP, with voting and dispositive power over the shares held by TVM VI LP. TVM VI Management, Birner, Schuhsler and Fischer each disclaim beneficial ownership of the shares held by TVM VI LP, except to the extent of any pecuniary interest therein, if any. Read SEC document |
| September 19, 2017 Filed Sep 27, 2017 18:34 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | OtherCommon Stock | 663,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000726 · edgar.xml · nonDerivative · entry 1 TVM Life Science Ventures VI GmbH & Co KG · CIK 0001599744 · Director · 10% owner TVM Life Science Ventures VI LP · CIK 0001318584 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · Director · 10% owner Birner Hubert · CIK 0001398598 · Director · 10% owner Marengere Luc · CIK 0001639971 · 10% owner Fischer Stefan · CIK 0001398596 · 10% owner SCHUHSLER HELMUT · CIK 0001133921 · 10% owner Wanless Mark · CIK 0001718086 · 10% owner Leatt Gary · CIK 0001718117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 663,782 F1 · kind: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F1 · price: These shares were acquired pursuant to an Agreement and Plan of Merger, dated as of June 30, 2017 (the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Acer Therapeutics Inc. ("Acer"). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement) of the closing of the Mergers contemplated thereby, the then outstanding shares of Acer's common stock were cancelled and were automatically converted into the right to receive 1 share of the Issuer's common stock for each share of Acer common stock then held by the Reporting Persons. These shares were previously reported on a Form 3 filed by the Reporting Persons on the date of this filing. F2 · ownership.nature: The shares are directly held by TVM Life Science Ventures VI GmbH & Co. KG ("TVM VI"). Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), and Helmut Schuhsler ("Schuhsler") are members of the investment committee of TVM Life Science Ventures Management VI L.P. ("TVM VI Management"), a special limited partner of TVM VI, with voting and dispositive power over the shares held by TVM VI. TVM VI Management, Birner, Schuhsler and Fischer each disclaim beneficial ownership of the shares held by TVM VI, except to the extent of any pecuniary interest therein, if any. Birner is a director of the Issuer. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 658 | $10.30 Strike: $36.20 | $6,777.40 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · derivative · entry 6 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 658 shares Expires 2027-01-03 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,371 | $36.88 Strike: $9.62 | $87,442.48 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · derivative · entry 5 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,371 shares Expires 2026-07-01 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,897 | $40.26 Strike: $6.24 | $358,193.22 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · derivative · entry 4 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,897 shares Expires 2026-05-10 F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,449 | $38.00 Strike: $8.50 | $55,062.00 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · derivative · entry 3 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,449 shares Expires 2026-01-04 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,954 | $36.50 Strike: $10.00 | $217,321.00 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · derivative · entry 2 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,954 shares Expires 2025-05-05 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:20 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | OtherCommon Stock | 1,545,386 | $46.50 | $71,860,449.00 |
DisclosureSEC source: 0000911916-17-000076 · edgar.xml · nonDerivative · entry 1 Marengere Luc · CIK 0001639971 · Director · 10% owner TVM Life Science Ventures VII L.P. · CIK 0001640880 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TVM Life Science Ventures VII L.P. Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. F2 · ownership.nature: Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.